Saturday 17 October 2026
Export IART’s income statement to Excel — free account
Integra LifeSciences Holdings Corporation
IART Healthcare Medical Devices
Integra LifeSciences Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.6 billion, up 1.53% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 101.0%, free cash flow grew 193.5% and total debt rose 1.51%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
13.21
0.32
−2.37%
Follow IART
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(38.71%) | (39.90%) | (38.64%) | (0.70%) | |
Piotroski F-Score |
5 | 5 | 5 | 5 | |
| (12.85%) | (13.52%) | (13.00%) | (0.20%) | ||
ROIC |
(11.73%) | (11.87%) | (11.20%) | 1.58% | |
Return on Tangible Assets |
(40.70%) | (44.99%) | (38.98%) | (0.55%) | |
Average Days of Receivables |
58.24 | 62.24 | 58.69 | 59.19 | |
Free Cash Flow per Share |
(0.06) | (0.40) | 0.05 | 0.33 | |
Free Cash Flow |
(4.51) | (31.05) | 4.08 | 25.80 | |
Capital Expenditures |
(93.82) | (81.44) | (67.36) | (59.52) | |
| Other line items | |||||
Cash ROIC |
(0.15%) | (0.99%) | 0.13% | 0.82% | |
Accounts Receivable Turnover |
6.44 | 5.93 | 6.36 | 5.97 | |
Accounts Payable Turnover |
9.22 | 9.02 | 8.82 | 8.93 | |
Inventory Turnover |
1.69 | 1.74 | 1.68 | 1.64 | |
Average Days of Payables |
43.02 | 43.48 | 40.62 | 38.52 | |
Days of Inventory on Hand |
227.96 | 223.80 | 228.62 | 229.33 | |
Tax Rate |
(0.09) | (0.08) | (0.07) | 39.46 | |
Research and Development Expense of Revenue |
6.41% | 6.05% | 5.94% | 5.77% | |
Selling, General and Administrative Expense of Revenue |
43.15% | 42.79% | 42.35% | 41.82% | |
Share Based Compensation of Revenue |
1.21% | 1.14% | 1.33% | 1.36% | |
Interest Coverage |
(5.89) | (5.72) | (5.19) | 0.71 | |
Operating CF/Net income |
(0.18) | (0.10) | (0.14) | (11.78) | |
Depreciation/Fixed assets |
0.36 | 0.35 | 0.35 | 0.35 | |
Capex/Depreciation |
(0.60) | (0.52) | (0.43) | (0.38) | |
Revenue per Share |
21.41 | 21.33 | 21.37 | 21.32 | |
Operating CF per Share |
1.16 | 0.66 | 0.93 | 1.10 | |
Capex per Share |
(1.22) | (1.06) | (0.88) | (0.77) | |
Capex to Sales |
0.06 | 0.05 | 0.04 | 0.04 |
Columns are period end dates